Blood levels of tacrolimus (FK506) determined by three different methods, were com pared after intravenous (i.v.) and oral administration of 14C-FK506 to rats. The methods used were high performance liquid chromatography-mass spectrometry (LC/MS) with electrospray ionization mode, enzyme immunoassay (EIA) using anti-FK506 monoclonal antibody, and the counting of radioactivity. Also, the composition of the radioactivity in the whole blood and plasma of rats after i.v. and oral administration was analyzed by the high performance liquid chromatography (HPLC).
Introduction
FK506, a 23 membered macrolide antibiotic, is an immunosuppressive drug used for preventing or treating graft rejection after liver, kidney and/or bone marrow transplantation, and is in the clinical stage of development for other organ transplantation and autoimmune diseases. FK506 levels in the pharmacokinetic studies of FK506 have mainly been measured by enzyme im munoassay (EIA)1,I) and this method was used to estimate the pharmacokinetic parameters of FK506 in the rat3). Recently, we reported 8 metabolites produced from FK506 in the in vitro reaction system with rat liver microsomes and studied their immuno-reactivity with the anti-FK506 monoclonal antibody used for the determination of FK506 in the blood4 '5) . Although the 13-0-mono-desmethyl FK506 (M-I), which was most abundant in the in vitro system6), showed no immunoreactivity with the monoclonal an tibody, two O-mono-demethylated metabolites at the 15 and 31-carbon (M-III and M-II, respectively) and the 15-, 31-0-di-demethylated metabolite (M V) showed almost equal reactivity with the monoclonal antibody. These results raised the question to what extent the FK506 values determined by EIA corresponded to the unchanged FK506.
In this study, we established a method by high performance liquid chromatography-mass spectromet ry (LC/MS) specific for the determination of FK506 in the blood and compared the levels with the con centrations obtained by EIA and counting of radioactivity. We also studied the composition of radioactiv ity in the rat blood collected after intravenous (i.v.) and oral administration of 14C-FK506.
Materials and Methods

Materials
FK506 and FR900520 were biosynthesized at Fujisawa Pharmaceutical Co., Ltd (Fig. 1 ). 14C-labeled FK506 was biosynthesized in a medium containing 2,6-14C-pipecolic acid and Streptomyces tsukubaensis at Amersham Co. and purified by Fujisawa Pharmaceutical Co., Ltd. Specific radioactivity was 588.3
KBq/mg and radiochemical purity after purification was more than 97°o by thin-layer chromatography.
Metabolites of FK506, anti-FK506 monoclonal antibody, and FK506-conjugated peroxidase were ob tained as described previouslyl,4s>.
Animals and dosing
Male Sprague-Dawley strain rats (7 and 10 week old) were purchased from Clea Japan Inc. 14C-FK506 was dissolved in polyethylene glycol 400 and dosed to animals intravenously and orally at a dose level of 1.0 mg/kg. Heparinized blood samples were collected 0.25, 0.5, 1, 2 or 8 hours after ad ministration by cardiac puncture. The samples were stood for at least 30 min at room temperature to at tain equilibration of blood to plasma ratio of FK506 and plasma was separated at room temperature by centrifugation. The blood and plasma samples were stored frozen at 20°C until analyzed.
High performance liquid chromatography-mass spectrometry A half ml of whole blood or plasma was mixed with 1 ml of deionized (D.I.) water, 10,U1 of methanol or FK506 standard methanol solution (final FK506 concentration range; 0.5^-50 ng/ml whole blood or plasma), 10,ul of internal solution (50 ng/ml of FR900520 methanol solution), and 5 ml of mixture of dichloromethane/cyclohexane Table I . Selected ions for determination of FK506 were monitored at m/z 809.5 for FR900520 ammonium adduct and m/z 821.5 for FK506 ammonium adduct. The whole blood samples which exceeded the highest concentraion of the standard curve were diluted with rat blank whole blood. Analysis of radioactivity by high performance liquid chromatography Radioactivity in the blood samples was extracted to ethyl acetate and the extracted radioactivity was analyzed by high performance liquid chromatography (HPLC). One half ml of blood samples was mixed with 1.5 ml of 0.2 M phosphatebuffer (pH 7.0), 50 ul of methanol and 8 .8 ml of ethyl acetate, and was shaken for 30 min. The organic layer was separated and the layer (7.0 to 7.5 ml) collected was evaporat ed under a stream of nitrogen. The residue was dissolved in 50 ul of methanol and mixed with 220 ul of HPLC initial mobile phase (see below), and 200 ul of the sample was injected to the HPLC apparatus .
Operating conditions in HPLC are as described below.
The eluted solution was collected every 30 seconds from 1 to 31 min after injection.
Counting of radioactivity 
Results
Assay of FK506 levels
A specific assay for FK506 in the rat blood was established by electrospray LC/MS. The precision and accuracy of this method and EIA are shown in Table II .
In the LC/MS, accuracy and precision respectively ranged from 96 to 101% and from 5 to 16% at FK506 concentrations of 1 and 20 ng/ml.
In the EIA, accuracy and precision for FK506 determination in the whole blood were respectively from 102 to 119% and from 5.3 to 12.4% at FK506 concentrations of 2.0, 10 and 50 ng/ml. These parameters for the determination in the plasma respectively ranged from 90 to 119 % and from 6.0 to 11.5% at FK506 concentrations of 0.2, 1.0 and 5.0 ng/ml. At 0.25, 1, 2 and 8 hours after ix. injection, FK506 levels determined by LC/MS and EIA were almost equal in the whole blood and plasma of rats (Table III) . The results of linear regression analysis of the FK506 levels in the whole blood and plasma are depicted in Fig. 2 . The slopes of both regression lines were very close to one and the lines nearly passed through the origin of the coordinates. The values of radioactivity were higher than those determined by LC/MS and EIA in all blood samples (Table III) .
The ratio of values measured by LC/MS to those of radioactivity decreased with time after administra tion; the ratios in the whole blood were 0.77, 0.70, 0.62 and 0.59 at 0.25, 1, 2 and 8 hours after injection, respectively, and 0.69, 0.66, 0.59 and 0.24 in the plasma. After oral administration, the levels measured by EIA were slightly higher than those by LC/MS, and the ratio of the levels by EIA to LC/MS ranged from 1.1 to 1.3 and from 1.4 to 2.0 in the whole blood and plasma, respectively, as shown in Table III . Although the values measured by LC/MS and EIA were well correlated in the whole blood and plasma and both regression lines nearly passed through the origin of the coordinates, the slopes of the regression for the whole blood and plasma were 1.11 and 1.76, respectively (Fig. 2) . The values of radioactivity were higher than those measured by LC/MS and EIA in all blood samples as shown in Table III . The ratio of unchanged FK506 (determined by LC/MS) to radioactivity decreased gradually after administration; the ratios in the whole blood were 0.41, 0.38, 0.28 and 0.14 at 0.25, 1, 2 and 8 hours after dosing, respectively, and 0.08, 0.08, 0.04 and 0.04 in the plasma.
Analysis of radioactivity by HPLC After i.v. and oral administration of 14C-FK506 to rats at a dose level of 1 mg/kg, the radioactivity in the blood was extracted to ethyl acetate and was analyzed by reverse phase HPLC.
The extraction ratio of radioactivity to ethyl acetate is shown in Table IV . FK506 and M-I spiked to the whole blood and plasma were extracted completely to ethyl acetate. About 80% of radioactivity in both the whole blood and plasma 30 min after i.v. injection was extracted to ethyl acetate but the extrac tion ratio of radioactivity from the plasma 8 hours after injection and from the whole blood and plasma 15 min after oral administration lowered to about 40 to 60Y6 (Table IV) . Elution of the extracted radioac tivity by HPLC is depicted in Fig. 3 . Numerous small fractions of radioactivity eluted before the un changed FK506 and no major metabolite peaks were detected. Only the fraction eluted at the same reten tion time of M-I was observed in all the samples analyzed. The compositions of the unchanged FK506
and M-I were nearly 80 and 2 %, respectively, of the eluted fractions of radioactivity in the whole blood and plasma at 30 min after i.v. injection. The ratio of unchanged FK506 to eluted radioactivity was higher in the whole blood than the plasma, but the ratio of M-I was higher in the plasma when compared with the ratio in both samples at the same collection time. 
Discussion
To characterize the pharmacokinetic properties of a new chemical entity, the unchanged compound should be determined. FK506 contained no chromophore moiety in its structure, so it was very difficult to develop a method which was able to detect less than 1 ng/ml of FK506 in the blood by a specific method such as HPLC. We developed a sensitive EIA which was able to detect 0.05 ng/ml of FK506 in the blood',') and used this method to estimate the pharmacokinetic parameters of FK506 in the rat3). Re Under the extraction conditions of radioactivity in this study, FK506 and M-I were extracted com pletely to ethylacetate. Although 80% of radioactivity in the whole blood and plasma 30 min after i.v. in jection was extracted to ethyl acetate, the extraction ratio of radioactivity was about 40-60% in the plas ma 8 hours after i.v. injection and in the whole blood and plasma 15 min after oral administration. These results suggest that there exist metabolites more polar than FK506 and M-I in the whole blood and plas ma of rats.
The compositions of the unchanged FK506 and MA were about 80 and 2 %, respectively, of the elut ed fractions of radioactivity in the whole blood and plasma at 30 min after i.v. injection. The ratio of un changed FK506 to eluted radioactivity was higher in the whole blood than in the plasma but the ratio of M-I was higher in the plasma when compared to the ratio in either sample at the same collection time.
The results suggest that the composition of the metabolites in the total FK506 estimated by radio-activi ty was higher in the plasma than in the whole blood of rats treated with 14C-FK506.
The ratio of unchanged FK506 to radioactivity in the whole blood and plasma decreased with time af ter i.v. and oral administration to rats, suggesting that the portion of metabolites in the blood increased with time after administration of FK506.
